Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)

/PRNewswire/ -- Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S....

Related Keywords

United States ,American ,Ron Kuppersmith ,Rick Geoffrion ,American Academy Of Otolaryngology ,Drug Administration ,Cyrano Therapeutics ,Investigational New Drug ,Chief Executive Officer ,Chief Medical Advisor ,American Academy ,